#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14752	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2676	680.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1989	1989	T	933	T,G,C,A	925,4,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14752	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2676	680.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1723	1723	C	1003	C,A	1001,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14752	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2676	680.0	0	HET	.	.	.	C1320T,G	.	1320	1320	C	1859	1859	C	909	C,T,G	714,193,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25146	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3994	784.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2517	2517	C	900	C,A	897,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25146	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3994	784.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3143	3143	T	828	T,A,G	825,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25146	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3994	784.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2591	2591	A	831	A,C	830,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	27	32448	blaTEM	861	861	100.0	blaTEM.l15.c4.ctg.1	1937	2084.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	2328	folP	852	852	100.0	folP.l15.c17.ctg.1	2079	139.8	1	SNP	p	R228S	0	.	.	682	684	CGC	1260	1262	CGC	206;208;210	C;G,T,A;C	206;205,2,1;210	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5372	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3901	171.8	1	SNP	p	S91F	0	.	.	271	273	TCC	888	890	TCC	191;191;190	T;C;C,T,G	191;191;188,1,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5372	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3901	171.8	1	SNP	p	D95N	0	.	.	283	285	GAC	900	902	GAC	191;190;190	G;A;C,A	191;190;189,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5372	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3901	171.8	1	SNP	p	D95G	0	.	.	283	285	GAC	900	902	GAC	191;190;190	G;A;C,A	191;190;189,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	539	1950	mtrR	633	633	99.53	mtrR.l15.c4.ctg.1	1741	139.5	0	.	p	.	0	L15P	NONSYN	43	45	CTG	628	630	CCG	208;208;210	C,G;C;G	206,1;207;210	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1092	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1493	91.3	0	.	n	.	0	G33.	DEL	33	33	G	650	650	G	212	G	212	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4838	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3372	178.7	1	SNP	p	D86N	0	.	.	256	258	GAC	820	822	GAC	241;241;243	G;A,T,C;C	241;239,1,1;243	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4838	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3372	178.7	1	SNP	p	S88P	0	.	.	262	264	TCC	826	828	TCC	238;240;239	T;C;C	238;240;239	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4296	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3188	167.7	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2339	2341	AAC	187;190;190	A;A,G;C	187;189,1;190	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4296	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3188	167.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1736	1738	GGC	246;247;246	G,C,A;G;C	244,1,1;247;246	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1475	1477	GCA	253;250;250	G;C;A	253;250;250	penA.1.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1478	1480	ATC	250;252;251	A;T,C;C,G,A	250;251,1;249,1,1	penA.1.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1490	1492	GTG	244;245;247	G;T,C,G;G	244;242,2,1;247	penA.1.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1490	1492	GTG	244;245;247	G;T,C,G;G	244;242,2,1;247	penA.1.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1994	1996	ACC	260;259;256	A,T;C,A;C	257,3;257,2;256	penA.1.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2048	2050	GCG	245;244;240	G;C,G;G,T,C	245;243,1;238,1,1	penA.1.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2048	2050	GCG	245;244;240	G;C,G;G,T,C	245;243,1;238,1,1	penA.1.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2171	2173	GGC	226;228;227	G;G,A;C	226;227,1;227	penA.1.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2180	2182	GGC	230;232;233	G;G;C,G	230;232;231,2	penA.1.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.1.001	penA.1.001	1	1	27	4228	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2899	181.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2198	2200	CCG	223;225;221	C,A,G;C;G,T	220,2,1;225;220,1	penA.1.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5556	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3532	196.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2500	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2169	143.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	737	737	C	201	C	201	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	12	14	TTA	31;32;37	T;T;A	31;32;37	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	57	59	CAT	65;65;65	C;A;T	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	60	62	AGT	65;65;65	A;G;T	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	69	71	TAC	65;65;65	T;A;C	65;65;65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	R307E	NONSYN	919	921	AGA	159	161	GAA	1;1;1	G;A;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	171	173	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	180	182	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	186	188	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	192	194	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	195	197	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	198	200	GCC	1;1;2	G;C;C	1;1;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	296	porB1a	984	222	90.99	porB1a.l15.c17.ctg.3	290	29.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	204	206	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	0	.	p	.	0	E38A	NONSYN	112	114	GAA	492	494	GCA	247;250;247	G;C;A	247;250;246	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	0	.	p	.	0	E134Q	NONSYN	400	402	GAG	780	782	CAG	232;235;236	C,A;A,C;G	231,1;234,1;236	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	807	809	GGA	225;226;227	G;G,C;A	225;225,1;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1011	1011	T	275	T	275	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	1	SNP	p	G120K	0	.	.	358	360	GGT	738	740	GGT	227;226;228	G;G;T	227;226;228	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	1	SNP	p	A121D	0	.	.	361	363	GCC	741	743	GCC	228;229;228	G,A;C,G;C	226,2;228,1;228	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2930	porB1b	1035	1035	98.19	porB1b.l15.c30.ctg.1	1562	223.8	1	SNP	p	A121N	0	.	.	361	363	GCC	741	743	GCC	228;229;228	G,A;C,G;C	226,2;228,1;228	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9538	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5241	226.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2248	2250	CAT	243;241;242	C;A,T;T,G,A	243;240,1;240,1,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1420	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1498	118.2	1	SNP	p	V57M	1	.	.	169	171	ATG	758	760	ATG	264;266;266	A;T;G	264;266;266	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
